Abstract

Aim: To evaluate the clinical features of Kingella kingae osteoarticular infections. Method: We performed a retrospective audit of all children from whom we received a specimen for K. kingae real-time PCR (targeting rtxA and cpn60), as well as children with positive culture results from joint specimens, between May 2019 and April 2021. Microscopy and culture was performed according to standard protocols. Results: Fifty-six children with features of osteoarticular infection subsequently confirmed by imaging, were included. The median age of children with K. kingae detected, compared to other pathogens, was 19 months versus 9 years. 53% versus 17% had recent respiratory infection. Median CRP was 32 versus 62 mg/L. Organisms were seen on fluid microscopy in 0% versus 67% of patients. 0% versus 28% grew the pathogen from blood cultures. Cefazolin was chosen for inpatient directed therapy in 82% versus 16% of cases. K. kingae was cultured from joint aspirates in only 2 cases. Discussion: Patients with K. kingae septic arthritis have distinct clinical features, and molecular tests are important to confirm the diagnosis and direct targeted therapy. Molecular tests appear much more sensitive than routine culture for detection of K. kingae infection.1 1.Ilharreborde B, Bidet P, Lorrot M, et al. New real-time PCR-based method for Kingella kingae DNA detection: application to samples collected from 89 children with acute arthritis. J Clin Microbiol 2009; 47: 1837–41.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.